Literature DB >> 30707354

The Role of PI3K/Akt and ERK in Neurodegenerative Disorders.

Sachchida Nand Rai1, Hagera Dilnashin1, Hareram Birla1, Saumitra Sen Singh1, Walia Zahra1, Aaina Singh Rathore1, Brijesh Kumar Singh2, Surya Pratap Singh3.   

Abstract

Disruption of Akt and Erk-mediated signal transduction significantly contributes in the pathogenesis of various neurodegenerative diseases (NDs), such as Parkinson's disease, Alzheimer's diseases, Huntington's disease, and many others. These regulatory proteins serve as the regulator of cell survival, motility, transcription, metabolism, and progression of the cell cycle. Therefore, targeting Akt and Erk pathway has been proposed as a reasonable approach to suppress ND progression. This review has emphasized on involvement of Akt/Erk cascade in the neurodegeneration. Akt has been reported to regulate neuronal toxicity through its various substrates like FOXos, GSK3β, and caspase-9 etc. Akt is also involved with PI3K in signaling pathway to mediate neuronal survival. ERK is another kinase which also regulates proliferation, differentiation, and survival of the neural cell. There has also been much progress in developing a therapeutic molecule targeting Akt and Erk signaling. Therefore, improved understanding of the molecular mechanism behind the regulatory aspect of Akt and Erk networks can make strong impact on exploration of the neurodegenerative disease pathogenesis.

Entities:  

Keywords:  6-OHDA, 6-hydroxydopamine; BDNF, brain-derived neurotrophic factor; HD, Huntington disease; MAPK, mitogen-activated protein-extracellular kinase; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NDs, neurodegenerative disorders; Nrf2, nuclear factor erythroid 2 p45-related factor 2; PD, Parkinson’s disease

Mesh:

Substances:

Year:  2019        PMID: 30707354     DOI: 10.1007/s12640-019-0003-y

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  169 in total

Review 1.  The development and therapeutic potential of protein kinase inhibitors.

Authors:  P Cohen
Journal:  Curr Opin Chem Biol       Date:  1999-08       Impact factor: 8.822

Review 2.  Ion channels as physiological effectors for growth factor receptor and Ras/ERK signaling pathways.

Authors:  S G Rane
Journal:  Adv Second Messenger Phosphoprotein Res       Date:  1999

Review 3.  Regulation of tyrosine kinase cascades by G-protein-coupled receptors.

Authors:  L M Luttrell; Y Daaka; R J Lefkowitz
Journal:  Curr Opin Cell Biol       Date:  1999-04       Impact factor: 8.382

4.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

Authors:  A Brunet; A Bonni; M J Zigmond; M Z Lin; P Juo; L S Hu; M J Anderson; K C Arden; J Blenis; M E Greenberg
Journal:  Cell       Date:  1999-03-19       Impact factor: 41.582

5.  Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit.

Authors:  S S Kang; T Kwon; D Y Kwon; S I Do
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

6.  MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia.

Authors:  A Alessandrini; S Namura; M A Moskowitz; J V Bonventre
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

7.  Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.

Authors:  D Fulton; J P Gratton; T J McCabe; J Fontana; Y Fujio; K Walsh; T F Franke; A Papapetropoulos; W C Sessa
Journal:  Nature       Date:  1999-06-10       Impact factor: 49.962

8.  NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling.

Authors:  J A Romashkova; S S Makarov
Journal:  Nature       Date:  1999-09-02       Impact factor: 49.962

9.  NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase.

Authors:  O N Ozes; L D Mayo; J A Gustin; S R Pfeffer; L M Pfeffer; D B Donner
Journal:  Nature       Date:  1999-09-02       Impact factor: 49.962

10.  Depolarization and neurotrophins converge on the phosphatidylinositol 3-kinase-Akt pathway to synergistically regulate neuronal survival.

Authors:  A R Vaillant; I Mazzoni; C Tudan; M Boudreau; D R Kaplan; F D Miller
Journal:  J Cell Biol       Date:  1999-09-06       Impact factor: 10.539

View more
  73 in total

Review 1.  RETRACTED ARTICLE: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Authors:  Fei Xu; Lixin Na; Yanfei Li; Linjun Chen
Journal:  Cell Biosci       Date:  2020-04-01       Impact factor: 7.133

2.  Combined treatment of AT101 and demethoxycurcumin yields an enhanced anti-proliferative effect in human primary glioblastoma cells.

Authors:  Moiken Mehner; Carolin Kubelt; Vivian Adamski; Christina Schmitt; Michael Synowitz; Janka Held-Feindt
Journal:  J Cancer Res Clin Oncol       Date:  2019-12-16       Impact factor: 4.553

3.  The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson's disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway.

Authors:  Piniel Alphayo Kambey; Ma Chengcheng; Guo Xiaoxiao; Ayanlaja Abiola Abdulrahman; Kouminin Kanwore; Iqra Nadeem; Wu Jiao; Dianshuai Gao
Journal:  Metab Brain Dis       Date:  2021-01-28       Impact factor: 3.584

Review 4.  Cenobamate: Neuroprotective Potential of a New Antiepileptic Drug.

Authors:  Michał Wiciński; Oskar Puk; Bartosz Malinowski
Journal:  Neurochem Res       Date:  2020-11-30       Impact factor: 3.996

Review 5.  Neuroprotection by Mucuna pruriens in Neurodegenerative Diseases.

Authors:  Walia Zahra; Hareram Birla; Saumitra Sen Singh; Aaina Singh Rathore; Hagera Dilnashin; Richa Singh; Priyanka Kumari Keshri; Priyanka Gautam; Surya Pratap Singh
Journal:  Neurochem Res       Date:  2022-04-05       Impact factor: 3.996

Review 6.  Mucuna pruriens in Parkinson's and in some other diseases: recent advancement and future prospective.

Authors:  Sachchida Nand Rai; Vivek K Chaturvedi; Payal Singh; Brijesh Kumar Singh; M P Singh
Journal:  3 Biotech       Date:  2020-11-10       Impact factor: 2.406

7.  Triclosan induces PC12 cells injury is accompanied by inhibition of AKT/mTOR and activation of p38 pathway.

Authors:  Shao-Jun Li; Pan Chen; Tanara Vieira Peres; Beatriz Ferrer Villahoz; Ziyan Zhang; Mahfuzur R Miah; Michael Aschner
Journal:  Neurotoxicology       Date:  2019-08-02       Impact factor: 4.294

8.  SRY-Box 21 Antisense RNA 1 Knockdown Diminishes Amyloid Beta25-35-Induced Neuronal Damage by miR-132/PI3K/AKT Pathway.

Authors:  Fengming Gu; Daofei Ji; Hongzao Ni; Depeng Chen
Journal:  Neurochem Res       Date:  2021-06-19       Impact factor: 3.996

9.  Reversible Changes in BDNF Expression in MK-801-Induced Hippocampal Astrocytes Through NMDAR/PI3K/ERK Signaling.

Authors:  Wenjuan Yu; Hongwei Fang; Lei Zhang; Miaowen Hu; Sidi He; Huafang Li; Hao Zhu
Journal:  Front Cell Neurosci       Date:  2021-05-14       Impact factor: 5.505

10.  Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.

Authors:  Stylianos Ravanidis; Anastasia Bougea; Dimitra Karampatsi; Nikolaos Papagiannakis; Matina Maniati; Leonidas Stefanis; Epaminondas Doxakis
Journal:  Mov Disord       Date:  2021-01-12       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.